Format

Send to

Choose Destination
Lung Cancer. 2016 May;95:28-34. doi: 10.1016/j.lungcan.2016.02.010. Epub 2016 Feb 23.

Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.

Author information

1
Division of Health Services Research, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, 115 South Grand Ave., S525 PHAR, Iowa City, IA 52242, United States. Electronic address: mary-schroeder@uiowa.edu.
2
Graduate Program in Pharmaceutical Socioeconomics, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, 115 South Grand Ave., S532 PHAR, Iowa City, IA 52242, United States. Electronic address: yu-yu-tien@uiowa.edu.
3
Department of Epidemiology, College of Public Health, University of Iowa, 145 N. Riverside Drive, S441 CPHB, Iowa City, IA 52242, United States. Electronic address: kara-wright@uiowa.edu.
4
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. Electronic address: Halfdanarson.Thorvardur@mayo.edu.
5
Division of Hematology, Oncology, Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, 200 Hawkins Drive, C32 GH, Iowa City, IA 52242, United States. Electronic address: taher-hejleh@uiowa.edu.
6
Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Suite 303D, Columbia, SC 29208, United States. Electronic address: jbrooks2@mailbox.sc.edu.

Abstract

OBJECTIVES:

The purpose of this study was to assess to what extent geographic variation in adjuvant treatment for non-small cell lung cancer (NSCLC) patients would remain, after controlling for patient and area-level characteristics.

MATERIALS AND METHODS:

A retrospective cohort of 18,410 Medicare beneficiaries with resected, stage I-IIIA NSCLC was identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Adjuvant therapies were classified as adjuvant chemotherapy (ACT), postoperative radiation therapy (PORT), or no adjuvant therapy. Predicted treatment probabilities were estimated for each patient given their clinical, demographic, and area-level characteristics with multivariate logistic regression. Area Treatment Ratios were used to estimate the propensity of patients in a local area to receive an adjuvant treatment, controlling for characteristics of patients in the area. Areas were categorized as low-, mid- and high-use and mapped for two representative SEER registries.

RESULTS:

Overall, 10%, 12%, and 78% of patients received ACT, PORT and no adjuvant therapy, respectively. Age, sex, stage, type and year of surgery, and comorbidity were associated with adjuvant treatment use. Even after adjusting for patient characteristics, substantial geographic treatment variation remained. High- and low-use areas were tightly juxtaposed within and across SEER registries, often within the same county. In some local areas, patients were up to eight times more likely to receive adjuvant therapy than expected, given their characteristics. On the other hand, almost a quarter of patients lived in local areas in which patients were more than three times less likely to receive ACT than would be predicted.

CONCLUSION:

Controlling for patient and area-level covariates did not remove geographic variation in adjuvant therapies for resected NSCLC patients. A greater proportion of patients were treated less than expected, rather than more than expected. Further research is needed to better understand its causes and potential impact on outcomes.

KEYWORDS:

Adjuvant therapy; Elderly patients; Geographic treatment variation; Non-small cell lung cancer; SEER-Medicare

PMID:
27040848
PMCID:
PMC4823769
DOI:
10.1016/j.lungcan.2016.02.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center